A retrospective study of 69 patients with t(6;9)(p23;q34) AML emphasizes the need for a prospective, multicenter initiative for rare ‘poor prognosis’ myeloid malignancies

Slovak, Marilyn L.; Gundacker, Holly; Bloomfield, Clara D.; Dewald, Gordon W.; Appelbaum, Frederick R.; Larson, Richard A.; Tallman, Martin S.; Bennett, John M.; Stirewalt, Derek L.; Meshinchi, Soheil; Willman, Cheryl L.; Ravindranath, Yaddanapudi; Alonzo, Todd A.; Carroll, Andrew J.; Raimondi, Susana C.; Heerema, Nyla A.

doi:10.1038/sj.leu.2404233

Cited by 107 publications

(127 citation statements)

References 8 publications

Supporting

Mentioning

115

Contrasting

Unclassified

Order By: Relevance

“…9,10 The current matchedpair analysis of the nationwide survey demonstrated that the OS and the non-relapse mortality, as well as the relapse rate, were independent of the presence of t(6;9)(p23;q34) in allogeneic HSCT recipients, thus suggesting that allogeneic HSCT may be able to overcome the unfavorable effect of t(6;9)(p23;q34) in AML patients.…”

Section: Discussionmentioning

confidence: 99%

“…[5][6][7][8] The translocation of chromosome (6;9)(p23;q34) forming the DEK/NUP214 fusion mRNA is observed in B1% of AML cases. 9 The characteristics of AML with t(6;9)(p23;q34) are known to include development at a younger age, 10 resistance to chemotherapy and a very poor prognosis. 9 Therefore, the presence of this karyotype in AML patients is an indication for HSCT; however, the impact of t(6;9)(p23;q34) on the outcome of HSCT remains unclear because of the rarity of this entity.…”

Section: Introductionmentioning

confidence: 99%

“…9 The characteristics of AML with t(6;9)(p23;q34) are known to include development at a younger age, 10 resistance to chemotherapy and a very poor prognosis. 9 Therefore, the presence of this karyotype in AML patients is an indication for HSCT; however, the impact of t(6;9)(p23;q34) on the outcome of HSCT remains unclear because of the rarity of this entity. We conducted a retrospective study to examine the outcomes of HSCT in AML patients with t(6;9)(p23;q34) using the data from the Japan Society for Hematopoietic Cell Transplantation Data Registry.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia with t(6;9)(p23;q34) dramatically improves the patient prognosis: a matched-pair analysis

et al. 2011

View full text Add to dashboard Cite

Acute myeloid leukemia (AML) with t(6;9)(p23;q34) is well known to have a poor prognosis treated with chemotherapy and autotransplantation. The presence of this karyotype is an indicator for allogeneic hematopoietic stem cell transplantation (HSCT); however, the impact of t(6;9)(p23;q34) on the HSCT outcome remains unclear. We conducted a matchedpair analysis of de novo AML patients with and without t(6;9)(p23;q34) using data obtained from the Japanese HSCT data registry. A total of 57 patients with t(6;9)(p23;q34) received transplants between 1996 and 2007, and 171 of 2056 normal karyotype patients matched for age, disease status at HSCT and graft source were selected. The overall survival, disease-free survival, cumulative incidence of relapse and the non-relapse mortality in t(6;9)(p23;q34) patients were comparable to those for normal karyotype patients. A univariate analysis showed that t(6;9)(p23;q34) had no significant impact on the overall survival. These findings suggest that allogeneic HSCT may overcome the unfavorable impact of t(6;9)(p23;q34) as an independent prognostic factor.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia with t(6;9)(p23;q34) dramatically improves the patient prognosis: a matched-pair analysis

et al. 2011

View full text Add to dashboard Cite

show abstract

“…A -7/del(7q) was found once, a t(9;22)(q24;q11) once. A three way complex t(6;9;Var) has been found in 3 instances [7]. The t(6;9) may be secondary to toxic exposure; in some instances.…”

Section: Discussionmentioning

confidence: 99%

“…The prognosis of patients carrying the t(6;9) is unfavourable. Overall survival in patients with t(6;9)(p23;q34 in AML is the unfavourable risk cytogenetics subgroup [7].…”

Section: Discussionmentioning

confidence: 99%

Sole Translocation (6;9)(p23;q34) in AML-ETO Negative AML-M2 Patient

Trivedi¹,

Patel²,

Varma³

et al. 2017

J Down Syndr Chr Abnorm

View full text Add to dashboard Cite

Acute myeloid leukemia (AML) is a heterogeneous group of disorders with regards to its pathology and molecular genetics features. Translocation (6;9)(p23;q34) is a cytogenetic aberration that can be found in specific subtypes of both AML and myelodysplastic syndrome. This translocation is associated with an unfavorable prognosis. The t(6;9) is found in myeloproliferative disorders with typical clinical characteristics. This translocation results in highly consistent abnormalities at the molecular level. Here, we describe a case of sole translocation (6;9)(p23;q34) in AML-ETO negative AML-M2 patient with conventional cytogenetic and Fluorescence In Situ Hybridization (FISH) study results.

show abstract

Acute Myeloid Leukemia

Johansson¹,

Harrison²

2010

Cancer Cytogenetics

View full text Add to dashboard Cite

A retrospective study of 69 patients with t(6;9)(p23;q34) AML emphasizes the need for a prospective, multicenter initiative for rare ‘poor prognosis’ myeloid malignancies

Cited by 107 publications

References 8 publications

Allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia with t(6;9)(p23;q34) dramatically improves the patient prognosis: a matched-pair analysis

Allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia with t(6;9)(p23;q34) dramatically improves the patient prognosis: a matched-pair analysis

Sole Translocation (6;9)(p23;q34) in AML-ETO Negative AML-M2 Patient

Acute Myeloid Leukemia

Contact Info

Product

Resources

About